Mobile

A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001128-19

A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the dose-response relationship among the three QD and three BID doses of oral BMS-562247 on the composite endpoint of adjudicated VTE events (asymptomatic and symptomatic DVT and non-fatal PE) and all cause death in subjects treated for 12+/- 2 days following elective unilateral total knee replacement surgery.

Critère d'inclusion

  • Prevention of asymptomatic and symptomatic deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE) in subjects undergoing knee replacement surgery

Liens